Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP104 Phase II pilot study in moderate to severely active Crohn's disease
2015-001678-17Phase 2Completed
- Sponsor
- Fast Forward Pharmaceuticals BV
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing FFP104 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Sep 2015; status: completed.
02
Drugs
FFP104
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-001678-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001678-17.